Testing for neuronal antibodies in first-episode psychosis – Asking the relevant questions
Section snippets
Where do we start?
Autoimmune encephalitis (AE) remains an essential differential diagnosis of first-episode psychosis (FEP) (Guasp et al., 2021). Patients with AE have pathogenic antibodies against neuronal proteins which interfere with their functions (Dalmau et al., 2008). While studies have emphasized a wide array of neuronal antibodies against both surface and intracellular antigens (Pollak et al., 2020), most have focused on the antibodies against the N-methyl-D-aspartate receptor (NMDAR), given the strong
Autoimmune encephalitis or autoimmune psychosis? (Graus and Dalmau, 2021)
The term AP was originally designated for patients with psychosis of suspected autoimmune origin who had serum neuronal antibodies (Graus and Dalmau, 2021). On the other hand, a definitive AE diagnosis requires the presence of neuronal antibodies in the CSF (Graus et al., 2016). While studies on antibodies in psychotic patients have mainly been restricted to serum samples (Pollak et al., 2020), the clinical significance of serum neuronal antibodies is unlikely relevant, since 1–5% of healthy
Where do we go from here?
Addressing these concerns, as well as common limitations of the real-world practice, Guasp et al. (2021) propose a new diagnostic algorithm in FEP:
- (1)
patients with FEP and accompanying neurological symptoms should have CSF testing, antibodies included;
- (2)
patients with FEP and absent neurological symptoms should have serum antibody testing (anti-NDMDAR antibodies first, as other antibodies are extremely rare in FEP with isolated psychiatric symptoms), along with brain MRI and EEG, and if any is
Financial disclosure
No funding or research grants were received in the course of study, research or assembly of the manuscript.
Funding source
None.
CRediT authorship contribution statement
D.P. drafted the manuscript and conceived the theoretical framework. N.G. assisted in conceiving the theoretical framework and worked on the manuscript. O.O.C. and I.V.M. supervised the project, provided feedback, and worked on the manuscript. All authors approved the final version of the manuscript.
Declarations of interest
None.
Acknowledgement
None.
References (10)
- et al.
Neural autoantibodies in cerebrospinal fluid and serum in clinical high risk for psychosis, first-episode psychosis, and healthy volunteers
Front. Psychiatry
(2021) - et al.
Seroprevalence of autoantibodies against brain antigens in health and disease
Ann. Neurol.
(2014) - et al.
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Lancet Neurol.
(2008) - et al.
Autoimmune encephalitis or autoimmune psychosis?
Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.
(2021) - et al.
A clinical approach to diagnosis of autoimmune encephalitis
Lancet Neurol.
(2016)
Cited by (2)
The relevance of anti-N-methyl-d-aspartate receptor encephalitis for psychiatrists
2024, International Journal of Psychiatry in Clinical PracticeThe Importance of Cerebrospinal Fluid Investigation in First-episode Psychosis
2023, Yale Journal of Biology and Medicine